|
|
Article: TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting.
- Article from:
- Business Wire
- Article date:
- April 14, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-Data also reveal peptide's synergistic interactions with anti-VEGF therapeutics-
CAMBRIDGE, Mass. -- TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of data that demonstrate anti-angiogenic properties of TM601. The findings from this mechanism of action study show that in addition to the high affinity tumor binding activity of TM601 that the compound may be an effective inhibitor of angiogenesis and tumor progression. The abstract was presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA by Dr. Douglas Jacoby, Senior Director of Research and ...